{"transactions":[{"id":942341,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2026-01-09T16:30:55.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of restricted common stock."}],"balance_after":1806319,"source":{"system":"sec-edgar","filing":"0001104659-26-002497","document":"tm262288-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465926002497/tm262288-2_4seq1.xml","form_type":"4"}},{"id":1315394,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2025-01-03T18:12:02.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 150,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 503,399 shares of restricted stock."}],"balance_after":1656319,"source":{"system":"sec-edgar","filing":"0001104659-25-000912","document":"tm251747-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465925000912/tm251747-3_4seq1.xml","form_type":"4"}},{"id":1357456,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2024-11-20T08:30:17.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":4.99,"value":9980.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average purchase price. The range of prices for the shares purchased was $4.98 to $4.99. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 353,399 shares of restricted stock."}],"balance_after":1506319,"source":{"system":"sec-edgar","filing":"0001104659-24-120876","document":"tm2428944-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465924120876/tm2428944-1_4seq1.xml","form_type":"4"}},{"id":1519263,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2024-05-13T08:49:08.000Z","date":"2024-05-10","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":6.29,"value":3145.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 353,399 shares of restricted stock."}],"balance_after":1504319,"source":{"system":"sec-edgar","filing":"0001104659-24-060262","document":"tm2414233-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465924060262/tm2414233-2_4seq1.xml","form_type":"4"}},{"id":1685790,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2024-01-05T16:31:07.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock will vest according to the following schedule: one-third on each of 01/3/2025, 01/3/2026, and 01/3/2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 353,399 shares of restricted stock."}],"balance_after":1503819,"source":{"system":"sec-edgar","filing":"0001104659-24-001825","document":"tm242141-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465924001825/tm242141-2_4seq1.xml","form_type":"4"}},{"id":1937049,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2023-03-28T08:30:14.000Z","date":"2023-03-27","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":11.55,"value":5775.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 48,399 shares of restricted stock and 175,000 restricted stock units."}],"balance_after":1373819,"source":{"system":"sec-edgar","filing":"0001104659-23-037421","document":"tm2310693-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465923037421/tm2310693-1_4seq1.xml","form_type":"4"}},{"id":2054882,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2023-01-13T17:05:12.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units will vest according to the following schedule: one-third on each of 01/12/2024, 01/12/2025, and 01/12/2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 48,399 shares of restricted stock and 175,000 restricted stock units."}],"balance_after":1373319,"source":{"system":"sec-edgar","filing":"0001104659-23-003866","document":"tm232835-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465923003866/tm232835-3_4seq1.xml","form_type":"4"}},{"id":2270643,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2022-05-16T08:31:09.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":300,"price":16.04,"value":4812.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.99 to $16.08. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 48,399 shares of restricted stock and 60,000 restricted stock units."}],"balance_after":1258319,"source":{"system":"sec-edgar","filing":"0001104659-22-060908","document":"tm2215423-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465922060908/tm2215423-1_4seq1.xml","form_type":"4"}},{"id":2270642,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2022-05-16T08:31:09.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":370,"price":14.76,"value":5461.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.60 to $15.05. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 48,399 shares of restricted stock and 60,000 restricted stock units."}],"balance_after":1258019,"source":{"system":"sec-edgar","filing":"0001104659-22-060908","document":"tm2215423-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465922060908/tm2215423-1_4seq1.xml","form_type":"4"}},{"id":2305086,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock","published_at":"2022-04-05T16:46:57.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 48,399 shares of restricted stock and 60,000 restricted stock units."}],"balance_after":1257649,"source":{"system":"sec-edgar","filing":"0001104659-22-042815","document":"tm2211420-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465922042815/tm2211420-3_4seq1.xml","form_type":"4"}},{"id":2408683,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock, par value $0.00001","published_at":"2022-02-08T18:01:09.000Z","date":"2022-02-07","kind":"purchase","acquired":true,"shares":800,"price":3.88,"value":3104.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.45 to $3.98. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 48,399 shares of restricted stock."}],"balance_after":1197649,"source":{"system":"sec-edgar","filing":"0001104659-22-014376","document":"tm225864-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465922014376/tm225864-3_4seq1.xml","form_type":"4"}},{"id":2408682,"issuer":{"id":5166,"kind":"organization","name":"Nuvectis Pharma, Inc."},"owners":[{"id":69681,"kind":"person","name":"Poradosu Enrique","position":1,"cik":"0001898147","reported_name":"Poradosu Enrique","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science & Business Off"}}],"security":"Common Stock, par value $0.00001","published_at":"2022-02-08T18:01:09.000Z","date":"2022-02-04","kind":"purchase","acquired":true,"shares":3800,"price":3.35,"value":12730.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.25 to $3.43. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 48,399 shares of restricted stock."}],"balance_after":1196849,"source":{"system":"sec-edgar","filing":"0001104659-22-014376","document":"tm225864-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898147/000110465922014376/tm225864-3_4seq1.xml","form_type":"4"}}]}